Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Рациональная комбинированная терапия приступа мигрени
Рациональная комбинированная терапия приступа мигрени
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Азимова Ю.Э., Сергеев А.В., Осипова В.В., Табеева Г.Р. Диагностика и лечение головных болей в России: результаты анкетного опроса врачей. Рос. журн. боли. 2010; 4: 12–7.
2. Данилов А.Б., Подымова И.Г., Филатова Е.Г. и др. Лечение мигренозного приступа: эффективность и безопасность. Cons. Med. 2013; 15 (2).
3. Табеева Г.Р. Специфическое лечение мигрени: история одного триптана. Журн. невропатол. и психиатр. им. С.С.Корсакова. 2007; 5: 75–8.
4. Табеева Г.Р., Яхно Н.Н. Мигрень. М.: ГЭОТАР-Медиа. 2010.
5. Ayzenberg I, Katsarava Z, Sborowski A et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia 2012; 32 (5): 373–81.
6. Barnes NM, Andrade R, Bockaert J et al. 5-Hydroxytryptamine receptors, introductory chapter. IUPHAR database (IUPHAR-DB). Available at: http://www.iuphar-db.org/DATABASE/FamilyIntroductionForward?familyId=1. Accessed March 5, 2012.
7. Dahlöf C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993; 13: 166–71.
8. Dahlöf C, Maassen Van Den Brink A. Dihydroergotamine, Ergotamine, Methysergide and Sumatriptan – Basic Science in Relation to Migraine Treatment. Headache 2012; 52 (4): 707–14.
9. Drees-Kulow ML. Experiences with a migraine compound in medical practice. A multicenter study with Avamigran. ZFA (Stuttgart) 1983; 59: 215–8.
10. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 2007; 13: 39–44.
11. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain 1996; 119: 249–56.
12. Lipton RB, Stewart WF, Diamond S et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41 (7): 646–57.
13. Matchar DB, Young WB, Rosenberg JH et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. U.S. Headache Consortium. Retrieved April 2002; from: www.aan.com/public/practiceguidelines/03.pdf.
14. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol 2000; 57 (3): 418–20.
15. Müller-Schweinitzer E. Ergot alkaloids in migraine: It the effect via 5-HT receptors? In: Olesen J, Saxena PR. 5-Hydroxytryptamine Mechanisms in Primary Headaches. New York, NY: Raven. 1992; p. 297–304.
16. Rapoport A. What Happens to the Old Headache Medicines? Headache 2012; 52 (4): 701–6.
17. Rasmussen BK., Jensen R., Schroll M. Epidemiology of headache in a general population – prevalence study. J Clin Epidemiol 1991; 44: 1147–57.
18. Silberstein SD, Hargreaves RJ. The history and pharmacology of ergotamine and dihydroergotamine. In: Diener HC, ed. Drug Treatment of Migraine and Other Frequent Headaches. Basel: Karger Press 2000; p. 52–65.
19. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Head Pain 2013; 14: 1.
20. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60: 1259–87.
21. Tfelt-Hansen P, Saxena PR, Dahlöf C et al. Ergotamine in the acute treatment of migraine Brain. 2000; 123 (1): 9–18.
22. Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 2008; 28: 877–86.
23. Van den Broek RW, Bhalla P, Van Den Brink AM et al. Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization. Cephalalgia 2002; 22: 83–93.
2. Данилов А.Б., Подымова И.Г., Филатова Е.Г. и др. Лечение мигренозного приступа: эффективность и безопасность. Cons. Med. 2013; 15 (2).
3. Табеева Г.Р. Специфическое лечение мигрени: история одного триптана. Журн. невропатол. и психиатр. им. С.С.Корсакова. 2007; 5: 75–8.
4. Табеева Г.Р., Яхно Н.Н. Мигрень. М.: ГЭОТАР-Медиа. 2010.
5. Ayzenberg I, Katsarava Z, Sborowski A et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia 2012; 32 (5): 373–81.
6. Barnes NM, Andrade R, Bockaert J et al. 5-Hydroxytryptamine receptors, introductory chapter. IUPHAR database (IUPHAR-DB). Available at: http://www.iuphar-db.org/DATABASE/FamilyIntroductionForward?familyId=1. Accessed March 5, 2012.
7. Dahlöf C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993; 13: 166–71.
8. Dahlöf C, Maassen Van Den Brink A. Dihydroergotamine, Ergotamine, Methysergide and Sumatriptan – Basic Science in Relation to Migraine Treatment. Headache 2012; 52 (4): 707–14.
9. Drees-Kulow ML. Experiences with a migraine compound in medical practice. A multicenter study with Avamigran. ZFA (Stuttgart) 1983; 59: 215–8.
10. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 2007; 13: 39–44.
11. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain 1996; 119: 249–56.
12. Lipton RB, Stewart WF, Diamond S et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41 (7): 646–57.
13. Matchar DB, Young WB, Rosenberg JH et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. U.S. Headache Consortium. Retrieved April 2002; from: www.aan.com/public/practiceguidelines/03.pdf.
14. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol 2000; 57 (3): 418–20.
15. Müller-Schweinitzer E. Ergot alkaloids in migraine: It the effect via 5-HT receptors? In: Olesen J, Saxena PR. 5-Hydroxytryptamine Mechanisms in Primary Headaches. New York, NY: Raven. 1992; p. 297–304.
16. Rapoport A. What Happens to the Old Headache Medicines? Headache 2012; 52 (4): 701–6.
17. Rasmussen BK., Jensen R., Schroll M. Epidemiology of headache in a general population – prevalence study. J Clin Epidemiol 1991; 44: 1147–57.
18. Silberstein SD, Hargreaves RJ. The history and pharmacology of ergotamine and dihydroergotamine. In: Diener HC, ed. Drug Treatment of Migraine and Other Frequent Headaches. Basel: Karger Press 2000; p. 52–65.
19. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Head Pain 2013; 14: 1.
20. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60: 1259–87.
21. Tfelt-Hansen P, Saxena PR, Dahlöf C et al. Ergotamine in the acute treatment of migraine Brain. 2000; 123 (1): 9–18.
22. Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 2008; 28: 877–86.
23. Van den Broek RW, Bhalla P, Van Den Brink AM et al. Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization. Cephalalgia 2002; 22: 83–93.
Авторы
Г.Р.Табеева
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.